Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs

Producción científica: Contribución a una revista › Carta › revisión exhaustiva

6 Citas (Scopus)

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

@article{ff2a88b030e54a0c9ddb82891cadd32a,

title = "Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs",

author = "Ivan Sisa and Estefania Noblecilla and Fadya Orozco",

year = "2021",

month = mar,

day = "6",

doi = "10.1016/S0140-6736(21)00357-3",

language = "Ingl{\'e}s",

volume = "397",

pages = "878",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "10277",

}

TY - JOUR

T1 - Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs

AU - Sisa, Ivan

AU - Noblecilla, Estefania

AU - Orozco, Fadya

PY - 2021/3/6

Y1 - 2021/3/6

UR - https://www.scopus.com/pages/publications/85101875192

U2 - 10.1016/S0140-6736(21)00357-3

DO - 10.1016/S0140-6736(21)00357-3

M3 - Carta

C2 - 33617776

AN - SCOPUS:85101875192

SN - 0140-6736

VL - 397

SP - 878

JO - The Lancet

JF - The Lancet

IS - 10277

ER -